Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX)

CUSIP: 74365A309

Q3 2022 13F Holders as of 30 Sep 2022

Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
80,165,500
Total 13F shares
3,548,189
Share change
+2,313,590
Total reported value
$3,696,081
Put/Call ratio
28%
Price per share
$1.04
Number of holders
26
Value change
+$2,398,630
Number of buys
6
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 74365A309?
CUSIP 74365A309 identifies PLX - Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) as of Q3 2022

As of 30 Sep 2022, Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) was held by 26 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,548,189 shares. The largest 10 holders included HIGHBRIDGE CAPITAL MANAGEMENT LLC, MEITAV DASH INVESTMENTS LTD, SUSQUEHANNA INTERNATIONAL GROUP, LLP, BRIDGEWAY CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, CAPITAL PERFORMANCE ADVISORS LLP, and TWO SIGMA ADVISERS, LP. This page lists 26 institutional shareholders reporting positions in this security for the Q3 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.